CRISPR/Cas9-based therapies hold considerable promise for the treatment of genetic diseases. Among these, Hutchinson-Gilford progeria syndrome, caused by a point mutation in the LMNA gene, stands out as a potential candidate. Here, we explore the efficacy of a CRISPR/Cas9-based approach that reverts several alterations in Hutchinson-Gilford progeria syndrome cells and mice by introducing frameshift mutations in the LMNA gene.
To test the efficacy of this approach, we cloned sgRNA-LCS1 or sgRNA-control in a lentiviral vector containing S. pyogenes Cas9 (lentiCRISPRv2) and used these to transduce Lmna +/+ and Lmna G609G/G609G murine fibroblasts. As a result, indels of variable length were produced in sgRNA-LCS1-transduced cells, as assessed by capillary electrophoresis-based fragment analysis (Extended Data Fig. 1 ). Immunoblot analysis showed a significant decrease in the accumulation of progerin and lamin A, while lamin C levels were not affected ( Fig. 1b) . Likewise, immunofluorescence analysis demonstrated that numbers of progerin-positive nuclei were reduced by 74% in sgRNA-LCS1-transduced cells compared to sgRNA-control-transduced cells (Fig. 1c ). Accordingly, we found a 65% decrease in the number of nuclear alterations in Lmna G609G/G609G cells transduced with sgRNA-LCS1compared to sgRNA-controltransduced cells (Fig. 1c) .
To test this system in human cells, we infected LMNA G608G/+ fibroblasts from HGPS patients and LMNA +/+ fibroblasts with these lentiviral vectors. Similar to mouse fibroblasts, we observed different indels in the DNA (Extended Data Fig. 2 ), a decrease in progerin and lamin A by immunoblot ( Fig. 1d) , an 83% decrease in progerin-positive nuclei and a 39% reduction in the number of aberrant nuclei in sgRNA-LCS1-versus sgRNA-control-transduced HGPS cells ( Fig. 1e ).
We next tested, in vivo, this editing approach using Lmna G609G/G609G mice as an HGPS animal model. We chose an adeno-associated virus 9 (AAV9) delivery vector due to its safety and broad tissue tropism. Given the packaging limit of these viruses (approximately 5 kb), we used Staphylococcus aureus Cas9 nuclease 15 and designed a new sgRNA against the same region in exon 11 with the 5′ -NNGRRT PAM sequence (sgRNA-LCS2). After packaging the vectors, with either sgRNA-LCS2 or the sgRNA-control, we injected intraperitoneally 2 × 10 11 AAV9 genome copies in P3 Lmna G609G/G609G mice ( Fig. 2a ). To assess editing efficiency, we performed Illumina sequencing of the target region in DNA from AAV9 target organsliver, heart, muscle and lung-of injected mice. Notably, Lmna contained indels in 13.6 ± 2.6% of the genome copies in liver, 5.3 ± 1.0% in heart, 4.1 ± 0.6% in muscle and 1.1 ± 0.2% in lung ( Fig. 2b,c ; Extended Data Fig. 3 ; Supplementary Tables 1-4 ). Given the modest fraction of cells edited in vivo, the global decrease in progerin messenger (RNA) was too low for reliable detection by quantitative reverse transcription polymerase chain reaction (RT-qPCR) (Extended Data Fig. 4 ). However, immunohistochemical analysis revealed a significant reduction in progerin-positive nuclei in liver, heart and skeletal muscle from sgRNA-LCS2-transduced mice 
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NAtuRE MEDICINE compared to sgRNA-control-transduced animals ( Fig. 2d ), which concurred with the DNA sequencing results. In lung, kidney and aorta, no reduction in the number of progerin-positive nuclei was observed, possibly due to the lower tropism of AAV9 in these organs (Extended Data Fig. 5 ). Given the importance of vascular alterations in HGPS, the lack of noticeable direct effects on the aorta is a setback of the approach tested. Nevertheless, vascular pathologies characteristic of HGPS such as atherosclerosis are strongly influenced by systemic factors. Therefore, a reliable assessment of potential vascular benefits will require the use of susceptible mouse models carrying additional genetic alterations, such as Apoe or Ldlr inactivation. Importantly, progerin reduction in AAV9-sgRNA-LCS2transduced mice was translated into an increase in their median survival of 33.5 days, from 127 to 160.5 days, compared to the sgRNA-control-transduced cohort, which represents a 26.4% lifespan increase ( Fig. 2e 6-189.2) . Likewise, maximum survival was extended from 151 to 212 days (P = 0.0163; one-tailed Fisher exact test) ( Fig. 2e ). Phenotypically, sgRNA-LCS2-transduced Lmna G609G/G609G mice presented a healthier appearance, with retarded loss of grooming, slightly improved body weight and increased blood glucose levels, partially rescuing the hypoglycemia characteristic of these mice ( Fig. 2f -h; Extended Data Figs. 7 and 8). Likewise, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis revealed that this group presented significantly fewer apoptotic cells in the kidney (Fig. 2i ). Since progerin reduction was not detected in this organ, this suggests an effect dependent on systemic factors. 
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We also observed a slight decrease in gastric mucosa atrophy (Extended Data Fig. 9 ) and reduced focal and perivascular fibrosis in heart and quadriceps muscle in sgRNA-LCS2-transduced compared to sgRNA-control-transduced mice, in accordance with the higher mobility of the former group ( Fig. 2j ; Supplementary Video 1). Antisense oligonucleotides blocking the aberrant splicing of LMNA transcripts have been proposed for the treatment of progeria 5, 16 . However, a longer-term therapy would be desirable. Here, we present a CRISPR/Cas9-based permanent genome-editing approach that targets LMNA exon 11, specifically interfering with lamin A/progerin expression. Because the Cas9 endonuclease is not directed specifically against the p.Gly608Gly point mutation, this strategy could also be applicable to laminopathies caused by other LMNA mutations 17 . However, although lamin A is dispensable in cells and mice 5, 6 , the consequences of abrogating its expression in humans remain unexplored. Therefore, alternative CRISPR/Cas9based systems, such as base editors 18 , also need to be tested. The coexistence of progeroid and normal cells at a ratio of approximately 50/50 in mosaic mice resulted in a completely normal phenotype and lifespan 14 . In the current work, although the editing efficiency is lower, extensive phenotype amelioration and lifespan extension were obtained. The extent to which the modest editing efficiency attained is due to low delivery efficacy could not be determined reliably, as the packaging limit of the vector precluded the inclusion of a suitable reporter. Interestingly, the concurrent study by Beyret and colleagues 19 describes another successful CRISPR/Cas9-based treatment of the Lmna G609G/G609G mouse model of HGPS. Nevertheless, further research on putative off-target events and adverse effects of the Cas9 nuclease will be needed to ensure the safety of this intervention. Regardless of these limitations, these two studies show the preclinical efficacy of genome editing in a mouse model of progeria and pave the way for using CRISPR/Cas9 in HGPS and other currently incurable systemic diseases.
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Methods
Plasmids and sgRNA cloning. All sgRNA-LCS were designed to target exon 11 of the LMNA gene using the Benchling CRISPR Design tool. For infections involving human and mouse fibroblasts, we used the lentiviral vector lentiCRISPRv2 (Addgene) in which we cloned the sgRNA-control (5′ -GGAGACGGGATACCGTCTCT-3′ ) or the sgRNA-LCS1 (5′ -AGCGCAGGTTGTACTCAGCG-3′ ). For AAV injection, we cloned the sgRNA-control or sgRNA-LCS2 (5′ -GTGCAGCGGCTCGGGGGACCCCG-3′ ) in the pX601-AAV vector from Addgene, containing the Cas9 nuclease from S. aureus.
Virus production. pX601-sgRNA-control or pX601-sgRNA-LCS2 plasmids were packaged as AAV serotype 9 by The Viral Vector Production Unit of the Universitat Autònoma de Barcelona (Barcelona, Spain), followed by polyethylene glycol precipitation and iodixanol gradient purification. Aliquots of 2 × 10 11 genome copies in 60 μ l of phosphate buffered saline (PBS)-MK were prepared for the injections.
Animal experiments. All animal experiments were performed in accordance with institutional guidelines and were approved by the Committee of Animal Experimentation of University of Oviedo (Oviedo, Spain). For AAV injection, P3 Lmna G609G/G609G mice were injected intraperitoneally with either sgRNA-control-or sgRNA-LCS2-containing vectors. All gene-editing and phenotypic analyses were performed at 3.5 months of age. To analyze blood glucose, animals were starved overnight and glucose levels were measured with an Accu-Check glucometer (Roche Diagnostics) using blood from the tail vein.
Histological analysis and TUNEL staining. Tissues were collected in 4% paraformaldehyde in PBS and embedded in paraffin. Hematoxylin and eosin (H&E) staining was performed on stomach tissue, and atrophy of the gastric mucosa was blindly evaluated by a pathologist on three different sections per mouse, establishing a pathological score (0, normal; 1, mild; 2, moderate; 3, severe athrophy). TUNEL staining in mouse kidneys was done according to the manufacturer's instructions (In-Situ Cell Death Detection Kit, TMR red, Roche).
To determine the number of TUNEL-positive nuclei, ten random fields per mouse were blindly analyzed using ImageJ. H&E with Gomori's trichrome staining was performed in heart and quadriceps muscle, and five random fields per tissue were quantified with a FIJI plugin provided by A. M. Nistal (Servicios Científico-Técnicos, Universidad de Oviedo).
Illumina sequencing and bioinformatic analysis.
MiSeq DNA sequencing was performed by Macrogen, using the Illumina 300bpPE. To prepare the library, DNA was isolated from liver, heart, muscle and lung from mice transduced with sgRNAcontrol-or sgRNA-LCS2-encoding AAVs. Next, we amplified the target region of the Cas9 nuclease with the Pfu DNA polymerase (Promega) adding the Illumina adapters by two PCRs: N GS 1_ fwd: A CA CT CT TT CC CT AC AC GA CG CT CT TC-CG AT CT NN NN TGTGACACTGGAGGCAGAAG and N GS 1_ rev: G TG AC TG-GA GT TC AG AC GT GT GC TC TT CC GA TC TC AAGTCCCCATCACTTGGTT for the first PCR, and NGS2_fwd: A ATGATACGGCGACCACCGAGAT CTACACTCTTTCCCTACACGACGCTCTTCCGATCT and NGS2_rev: CAAGCAGAAGACGGCATACGAGATXXXXXXGTGACTGGAGTTC for the second PCR. The N represents random bases and the X the sequence used for the index. Genomic reads in FASTQ format were aligned to the GRCm38.p6 assembly of the mouse genome using BWA v. 0.7.5a-r405 (ref. 20 ). Then, reads spanning the genomic region putatively affected by the CRISPR/Cas9 action (chr3: 88482555-88482615) were extracted with Samtools v. 1.3.1 (ref. 21 ) and analyzed using inhouse Perl scripts. Briefly, these scripts isolate the part of each read spanning the chosen region, highlight small insertions/deletions and output a count of each regional sequence. We then analyzed the percentage of the sequences showing regional differences in sgRNA-control-and sgRNA-LCS2-transduced mouse samples. Cell culture, transfection and viral transduction. We maintained HEK-293T cell cultures in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin-l-glutamine and 1% antibioticantimycotic (Gibco) at 37 °C in 5% CO 2 . In the case of human and mouse fibroblasts, × 1 non-essential amino acids, 10 mM HEPES buffer, 100 μ M 2-mercaptoethanol and × 1 sodium pyruvate (Gibco) were also added to the previous medium and 15% fetal bovine serum was used. For lentiviral infection, HEK-293T cells were transfected with lentiCRISPRv2 vector together with second-generation packaging plasmids using Lipofectamine reagent (Life Technologies). Supernatants were filtered through 0.45 μ m polyethersulfone filters to collect the viral particles, and added at 1:3 dilution to previously seeded human and mouse fibroblasts supplemented with 0.8 μ g ml -1 of polybrene (Millipore). Selection with puromycin (2 μ g ml -1 ) was performed 2 days after infection, and the editing efficiency and nuclear aberrations were quantified one week later.
RNA preparation and RT-qPCR.
Collected cells or tissues were homogenized in TRIzol reagent (Life Technologies) and RNA was extracted with the RNeasy Mini kit following the manufacturer's instructions (QIAGEN). cDNA was synthesized with the QuantiTect Reverse Transcription kit (QIAGEN) using 1 μ g of total RNA, and then RT-qPCR analysis of mouse tissues was performed. For progerin analysis, TaqMan PCR Universal Mastermix (Applied Biosystems) and the following oligonucleotides and probe were used: MmProgerin_fwd (5′ -TGAGTACAACCTGCGCTCAC-3′ ), MmProgerin_rev (5′ -TGGCAGGTCCCAGATTACAT-3′ ) and MmProgerin_probe (5′ -CGGGAGCCCAGAGCTCCCAGAA-3′ ); using a β -actin (Applied Biosystems) as endogenous control. For lamin C analysis, we used SYBR green PCR Universal Mastermix (Applied Biosystems) and the oligonucleotides Lmnc_fwd (5′ -CGACGAGGATGGAGAAGAGC-3′ ) and Lmnc_rev (5′ -AGACTTTGGCATGGAGGTGG-3′ ) for lamin C; or Actb_Fwd (5′ -CTGAGGAGCACCCTGTGCT-3′ ) and Actb_Rev (5′ -GTTGAAGGTCTCAAACATGATCTG-3′ ) for β -actin as endogenous control.
Protein isolation and immunoblot analysis. Cells were washed with × 1 PBS and homogenized in RIPA lysis buffer containing 100 mM Tris pH 7.4, 150 mM NaCl, 10 mM EDTA pH 8.0, 1% sodium deoxycholate, 1% Triton X-100 and 0.1% sodium dodecyl sulfate (SDS), supplemented with protease inhibitor cocktail (Complete, EDTA-free, Roche) and phosphatase inhibitors (PhosSTOP, Roche). Protein concentration was determined with the Pierce BCA Protein Assay Kit, and 30 µ g per lane were loaded onto 8% SDS-polyacrylamide gels. Gels were then transferred to nitrocellulose membranes, blocked with 5% nonfat dry milk in TBS-T buffer (20 mM Tris pH 7.4, 150 mM NaCl and 0.05% Tween 20) and incubated overnight at 4 °C with primary antibodies: 1:500 mouse monoclonal anti-lamin A/C (MANLAC1, provided by G. Morris) for experiments involving mouse cells, 1:1,000 rabbit polyclonal anti-lamin A/C (sc-20681, Santa Cruz Biotechnology) for experiments involving human cells or 1:10,000 anti-β -actin (AC-15, Sigma) as an endogenous control. Finally, blots were incubated with 1:10,000 goat anti-mouse (Jackson ImmunoResearch) or 1:3,000 goat anti-rabbit horseradish peroxidase (HRP) (Cell Signaling) in 1.5% nonfat dry milk in TBS-T and washed with TBS-T. Immunoreactive bands were developed with Immobilon Western chemiluminescent HRP substrate (Millipore) in a LAS-3000 Imaging System (Fujifilm). Bands were quantified using ImageJ.
Immunofluorescence, immunohistochemistry and nuclear morphology analysis. For immunofluorescence assays, cells were fixed in 4% paraformaldehyde solution, rinsed in PBS and permeabilized with 0.5% Triton X-100. Afterwards, they were blocked with 15% goat serum solution and incubated overnight at 4 °C with a rabbit polyclonal anti-progerin antibody in PBS (1:200). Next, slides were washed with TBS-T and incubated with 1:500 anti-rabbit secondary antibody Alexa Fluor 488 (Life Technologies). Nuclei were stained with 4′ ,6-diamidino-2phenylindole (DAPI, Invitrogen). In the case of immunohistochemical analysis, tissues were fixed in 4% paraformaldehyde solution and incubated with Target Retrieval Solution at 95 °C for 20 min, Peroxidase Blocking Solution for 5 min and Protein Block Serum Free (all from Dako) for 20 min before incubation with the anti-progerin primary antibody (1:300 dilution) for 1 h. An HRP-conjugated polyclonal anti-rabbit was applied for 30 min and then 3,3′ -diaminobenzidine for 10 min. Tissues were counterstained with hematoxylin (Dako) and visualized by light microscopy. Rabbit anti-progerin polyclonal antibody was generated using peptide immunogens and standard immunization procedures (S. Nourshargh et al., manuscript in preparation). The specificity of the antibody was confirmed by nuclear staining of Lmna G609G/G609G mouse-derived fibroblasts, which was negative in the case of WT cells. To determine the percentage of progerin-positive cells and nuclei with aberrations, five random fields per culture or tissue sample were blindly analyzed. For tissue samples, in each field a pre-established grid was used and five random areas were quantified.
Statistical analysis. Animals of the same age were used for comparisons between mice groups, and no statistical method was used to predict sample size. For statistical analysis of differences between mouse cohorts, normality was assessed using the Shapiro-Wilk test in those cases where n > 10. In the remaining cases, normality was assumed based on previous data and we performed two-tailed Student's t-test to study the statistical significance. For survival comparisons we used the log-rank test, and differences in maximum lifespan were calculated using the one-tailed Fisher exact test comparing the number of live sgRNA-control-and sgRNA-LCS2-transduced mice at the age corresponding to the 80th percentile of lifespan in the joint survival distribution. We used Microsoft Excel or GraphPad
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Experimental design 1. Sample size
Describe how sample size was determined.
Sample size was determined based on previous experiments of our laboratory, carried out with the same animal model under identical environmental conditions.
Data exclusions
Describe any data exclusions.
Two AAV9-treated mice (one from the control cohort and another one from the sgRNA-LCS2 group) were excluded from the survival plot due to perinatal death. This event could be explained by an early manipulation and a higher frailty of progeroid mice. The analysis of indel mutations in the liver of a LCS2-transduced mouse was also excluded due to a low number of reads in NGS (only 24 reads compared to more than 100,000 in the rest of analyzed samples). These exclusion criteria had not been pre-established.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Three independent infections were done for in vitro experiments. All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Allocation of both mice and cell cultures to each group was random.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Nuclear abnormalities and progerin analysis in cultures were quantified by investigators who were blinded to the identity of the analyzed cells. In the same way, histological analysis (Gomori staining, TUNEL assay and progerin immunohistochemistry) were also performed by investigators blinded to group identity. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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